Federico Nichetti, Medical Oncologist at Veneto Institute of Oncology, shared a post on LinkedIn:
“Warpspeed.sh ran an AI-based simulation of RASolute-302, predicting that daraxonrasib could demonstrate an advantage both in PFS and OS (>10 months!!) vs chemotherapy in pretreated patients with metastatic pancreatic cancer.
Will this be the real result?
Other articles featuring Federico Nichetti.